טוען...
Minnelide reduces tumor burden in preclinical models of osteosarcoma
Osteosarcoma is the most common bone cancer in children and adolescents with a five-year survival rate of about 70%. In this study, we have evaluated the preclinical therapeutic efficacy of the novel synthetic drug, Minnelide, a prodrug of triptolide on osteosarcoma. Triptolide was effective in sign...
שמור ב:
| הוצא לאור ב: | Cancer Lett |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4386634/ https://ncbi.nlm.nih.gov/pubmed/23499892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2013.02.050 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|